IMGN - ImmunoGen, Inc.

QQQ $ 431.01 $ 6.55 (1.54 %)

DIA $ 382.27 $ 1.39 (0.36 %)

SPY $ 508.26 $ 4.77 (0.95 %)

TLT $ 88.26 $ 0.46 (0.52 %)

GLD $ 216.60 $ 0.70 (0.32 %)

Previous Close

$ 31.23

Open

$ 31.24

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 31.22 - $ 31.25

52 Week Range

$ 3.61 - $ 31.25

Volume

48,606,862

Average Volume

Market Cap

8.32B

Beta (5Y Monthly)

$ 1.29

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	11-02-2023	09-30-2023	10-Q
2	07-31-2023	06-30-2023	10-Q
3	04-28-2023	03-31-2023	10-Q
4	03-01-2023	12-31-2022	10-K
5	11-04-2022	09-30-2022	10-Q
6	08-01-2022	06-30-2022	10-Q
7	05-06-2022	03-31-2022	10-Q
8	02-28-2022	12-31-2021	10-K
9	10-29-2021	09-30-2021	10-Q
10	07-30-2021	06-30-2021	10-Q
11	05-10-2021	03-31-2021	10-Q
12	03-01-2021	12-31-2020	10-K
13	11-06-2020	09-30-2020	10-Q
14	08-05-2020	06-30-2020	10-Q
15	05-05-2020	03-31-2020	10-Q
16	03-11-2020	12-31-2019	10-K
17	11-05-2019	09-30-2019	10-Q
18	08-07-2019	06-30-2019	10-Q
19	05-07-2019	03-31-2019	10-Q
20	03-01-2019	12-31-2018	10-K
21	11-02-2018	09-30-2018	10-Q
22	08-03-2018	06-30-2018	10-Q
23	05-09-2018	03-31-2018	10-Q
24	03-07-2018	12-31-2017	10-K
25	11-09-2017	09-30-2017	10-Q
26	08-04-2017	06-30-2017	10-Q
27	05-05-2017	03-31-2017	10-Q
28	11-04-2016	09-30-2016	10-Q
29	08-25-2016	06-30-2016	10-K
30	05-04-2016	03-31-2016	10-Q
31	02-04-2016	12-31-2015	10-Q
32	10-30-2015	09-30-2015	10-Q
33	08-27-2015	06-30-2015	10-K
34	05-08-2015	03-31-2015	10-Q
35	02-05-2015	12-31-2014	10-Q
36	10-30-2014	09-30-2014	10-Q
37	08-28-2014	06-30-2014	10-K
38	05-02-2014	03-31-2014	10-Q
39	02-05-2014	12-31-2013	10-Q
40	10-29-2013	09-30-2013	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

ImmunoGen Said Regarding AbbVie Merger, T...
02/08/2024 12:12:54

-8-K

abbvie-lifts-long-term-outlook-for-new-immunology-drugs-even-as-q4-revenue-and-profit-fall

AbbVie Lifts Long-Term Outlook For New Imm...
02/02/2024 16:12:37

AbbVie reports Q4 earnings with adjusted EPS at $2.79, beating consensus. Sees FY 2024 EPS of $11.05-$11.25. Raises 2027 outloo...

Immunogen Says On Jan 29 German Federal Ca...
01/29/2024 22:05:33

-SEC Filing

abbvies-transformational-2023-analyst-anticipates-growth-in-2024-amid-competitive-pressures

AbbVie's Transformational 2023, Analyst An...
01/29/2024 19:04:56

AbbVie's growth outlook in 2024 as William Blair upgrades, highlighting strong performance in Humira erosion management, st...

cramer-says-this-major-healthcare-stock-is-ridiculously-cheap-and-doing-so-many-great-things

Cramer Says This Major Healthcare Stock Is...
01/08/2024 13:53:11

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Realty Income (NYSE: O) and recommends staying with it....

10-health-care-stocks-whale-activity-in-todays-session

10 Health Care Stocks Whale Activity In To...
01/02/2024 17:35:29

upward-trajectory-for-biotechpharma-ma-sector-trends-towards-pre-pandemic-levels-forecasts-positive-for-2024

Upward Trajectory For Biotech/Pharma M&A: ...
12/29/2023 12:04:52

According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 bill...

bristol-myers-squibbs-mega-84b-oncology-bet---secures-exclusive-license-with-systimmune

Bristol Myers Squibb's Mega $8.4B Oncology...
12/12/2023 14:00:05

SystImmune and Bristol Myers Squibb & Co (NYSE: BMY)

10-health-care-stocks-with-whale-alerts-in-todays-session

10 Health Care Stocks With Whale Alerts In...
12/11/2023 17:35:24

ImmunoGen Presented Findings From Newly Di...
12/11/2023 08:08:45

Pivekimab Triplet Demonstrates Encouraging CR, Composite CR, and MRD Negativity Rates; Broad Anti-Leukemia Activity Observed ...

abbvies-new-9b-neuroscience-space-deal-might-attract-ftc-scrutiny-analyst-signals

AbbVie's New $9B Neuroscience Space Deal M...
12/07/2023 20:19:19

Wednesday, AbbVie Inc (NYSE: ABBV) agreed to acquire Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) for a total equity value ...

FDA Grants Priority Review of ImmunoGen's ...
12/05/2023 11:31:37

ImmunoGen, Inc. (NASDAQ:IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, ...

immunogen-abbvies-10b-deal-comes-at-right-time-analyst-says-in-downgrade-note

ImmunoGen, AbbVie's $10B Deal Comes At 'Ri...
12/04/2023 15:44:53

AbbVie Inc (NYSE: ABBV) is acquiring ImmunoGen, Inc. (NASDAQ: IMGN) for around $

Piper Sandler Downgrades Immunogen to Neut...
12/04/2023 13:06:29

Piper Sandler analyst Joseph Catanzaro downgrades Immunogen (NASDAQ:IMGN) from Overweight to Neutral and raises the price ta...

Barclays Downgrades Immunogen to Equal-Wei...
12/04/2023 10:31:53

Barclays analyst Peter Lawson downgrades Immunogen (NASDAQ:IMGN) from Overweight to Equal-Weight and raises the price target...

Barclays Downgrades Immunogen to Equal-Weight
12/01/2023 19:17:08

Barclays analyst Peter Lawson downgrades Immunogen (NASDAQ:IMGN) from Overweight to Equal-Weight.

Lululemon To Rally Around 16%? Here Are 10...
12/01/2023 15:22:10

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

Jefferies Downgrades Immunogen to Hold, An...
12/01/2023 11:40:12

Jefferies analyst Kelly Shi downgrades Immunogen (NASDAQ:IMGN) from Buy to Hold and announces $31 price target.

Guggenheim Downgrades Immunogen to Neutral...
12/01/2023 09:38:02

Guggenheim analyst Michael Schmidt downgrades Immunogen (NASDAQ:IMGN) from Buy to Neutral and raises the price target from $...

BMO Capital Downgrades Immunogen to Market...
12/01/2023 09:26:32

BMO Capital analyst Etzer Darout downgrades Immunogen (NASDAQ:IMGN) from Outperform to Market Perform and announces $31 pric...